ClinicalTrials.gg
RecruitingNCT06697093CaS-POLUpdated Apr 2, 2025

Polish Nationwide Registry of Diagnostics, Treatment and Outcome in Patients With Cardiogenic Shock

An observational study in Cardiogenic Shock, sponsored by Wroclaw Medical University. Recruiting at 2 sites in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-02.

Sponsored by Wroclaw Medical University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Study summary

The registry objective is to get information on current epidemiology, diagnostics, treatment and outcome in patients with cardiogenic shock in Poland. Obtained information will help to plan the nationwide initiative for modern cardiogenic shock treatment with established place for mechanical circulatory support.

It is hypothesized that the treatment and outcome of cardiogenic shock, including mechanical circulatory support, are currently poor in Poland and should be improved. Unfortunately, without status quo data, efficient planning for its improvement cannot be conducted, hence the CaS-POL registry initiative.

Read the detailed description

The prospective registry will be open in nature; any cardiology department in Poland with access to a 24-hour hemodynamic laboratory will be eligible to participate in the study. All participants will use an electronic CRF (Case Report Form) to anonymously collect data on the incidence, etiology, diagnosis, treatment approaches, and prognosis of patients with cardiogenic shock. Data will be collected by researchers from the medical documentation of participating centers. The data collection period will span six months, followed by a six-month prospective observation through visit in person, per telephone contact to the patient or his/her relatives or by retracting National Health Fund data in case the contact to the patient or his/her relatives is impossible.

To enable comparison with global data, collected information will include, among other aspects, the latest Society for Cardiovascular Angiography and Interventions (SCAI) classification for cardiogenic shock, the availability and application of modern short- and long-term mechanical circulatory support techniques, and the frequency of heart transplants.

02

Conditions studied

  • Cardiogenic Shock

Keywords

  • mechanical circulatory support
  • myocardial infarction
  • Cardiogenic shock
03

In context

Shock, Cardiogenic

297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.

This study's planned enrollment of 500 is above the median of 200 across 156 observational studies indexed under Shock, Cardiogenic.

Browse Shock, Cardiogenic studies →

Lead sponsor

Wroclaw Medical University is the lead sponsor of 99 studies on the registry; 29 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients admitted to the Intensive Care Unit (ICU) in the Cardiology, Cardiac Surgery, or to the Anesthesiology departments with a clinically evident cardiac etiology of shock.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cardiogenic shock patients of all etiologies in SCAI stage B, C, D, E.
  • age > 18 years old
  • persistent hemodynamic failure defined as systolic blood pressure of \<90 mmHg for ≥ 30 minutes or the requirement for inotropic or vasopressor agents with evidence of hypoperfusion of the peripheral organs

Exclusion criteria

Exclusion Criteria:

  • patients without return of spontaneous circulation who were considered to extracorporeal cardiopulmonary resuscitation (ECPR)
  • primary septic, anaphylactic, hypovolemic shock
  • post-operative cardiogenic shock
  • end-stage of heart failure disqualified from mechanical circulatory support and heart transplantation
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes

Groups and cohorts

  • cardiogenic shock patients

    The registry will include all patients presenting with primary cardiogenic shock. All medical interventions will be conducted based on established clinical indications.

06

What researchers measure

Primary outcomes

  1. all-cause mortality

    all-cause mortality

    Time frame: From the date of cardiogenic shock diagnosis recognition until the date of death from any cause assessed up to 6 months

Secondary outcomes

  1. myocardial infarction

    Recurrent myocardial infarction following an initial event

    Time frame: From the date of cardiogenic shock diagnosis recognition until the date of first documented myocardial infarction assessed up to 6 months

  2. stroke

    stroke following an initial event

    Time frame: From the date of cardiogenic shock diagnosis recognition until the date of first documented stroke assessed up to 6 months

  3. heart transplantation

    Heart transplantation in patients without myocardial recovery following cardiogenic shock.

    Time frame: From the date of cardiogenic shock diagnosis recognition until the date of heart transplantation assessed up to 6 months

  4. long-term LVAD implantation

    Long-term LVAD implantation in patients without myocardial recovery following cardiogenic shock

    Time frame: From the date of cardiogenic shock diagnosis recognition until the date of long-term LVAD assessed up to 6 months

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2025; primary completion for Apr 2026, 12 months later.

Of 79 non-industry observational studies under Shock, Cardiogenic, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 19. This study's planned 12 months is below that.

Counting every sponsor, half of 85 studies reached it within 45 months; a quarter within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2024
First posted
Nov 20, 2024
StartEst.
Apr 1, 2025
Primary completionEst.
Apr 1, 2026
CompletionEst.
Dec 31, 2026
Last update
Apr 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06697093
Lead sponsor
Wroclaw Medical University
Collaborators
Polish Cardiac Society, Johnson & Johnson
Responsible party
Wiktor Kuliczkowski (MD, PhD, Associate Professor, Head of the Catheterization Laboratory at Wroclaw University Hospital, Wroclaw Medical University) — Principal investigator
First posted
Nov 20, 2024
Start date
Apr 1, 2025 (estimated)
Primary completion
Apr 1, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 2, 2025

Study contacts

Wiktor Kuliczkowski, MD,PhD
Contact
wiktor.kuliczkowski@umw.edu.pl
+48 71 736 42 51
Mikołaj Błaziak, MD
Contact
blaziak.mikolaj@gmail.com
+48 71 736 42 51

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion